[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-kidney-injuries\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-kidney-injuries":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,79,102,125,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627235","the-association-between-preoperative-hba1c-levels-and-postoperative-acute-kidney-injury-in-isolated-coronary-artery-bypass-surgery-100627235",false,"NCT07445997","The Association Between Preoperative HbA1c Levels and Postoperative Acute Kidney Injury in Isolated Coronary Artery Bypass Surgery","\"The Association Between Preoperative HbA1c Levels and Postoperative Acute Kidney Injury in Isolated Coronary Artery Bypass Surgery: A Prospective Observational Study\"","Inclusion Criteria:\n\n* Patients undergoing isolated elective CABG surgery\n* Patients with available preoperative and postoperative Doppler RRI measurements\n* Patients with available HbA1c data\n\nExclusion Criteria:\n\n* Patients with chronic kidney disease\n* Emergency surgeries\n* Redo\u002Frevision surgeries\n* Patients undergoing concomitant valve surgery\n* Presence of acute infection or sepsis\n* Advanced heart failure (EF \\\u003C30%)\n* Requirement for intra-aortic balloon pump, pacemaker, or mechanical circulatory support\n* History of nephrectomy or single kidney\n* Preoperative serum creatinine \\>2.0 mg\u002FdL\n* Pregnancy\n* Refusal to participate in the study","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","7 Days","OBSERVATIONAL","Renal complications are frequently encountered in cardiac surgery and constitute significant causes of morbidity and mortality. They most commonly present in the form of acute kidney injury (AKI). The etiological factors of AKI include hemodynamic alterations, hemolysis and pigment nephropathy, inflammatory response and cytokine storm, ischemia-reperfusion injury, use of nephrotoxic agents, patient-related risk factors (advanced age, diabetes mellitus, preoperative renal insufficiency, congestive heart failure, hypertension, anemia), duration of surgery, and postoperative complications such as low cardiac output syndrome, sepsis, bleeding and reoperation, hypoalbuminemia, and fluid imbalance.\n\nPrevious studies have demonstrated several mechanisms through which elevated HbA1c levels may contribute to acute renal injury, including glomerular damage and hyperfiltration, endothelial dysfunction and microvascular injury, tubular damage, accumulation of glycation products and advanced glycation end products (AGEs), structural changes in blood vessels, and metabolic and systemic factors.\n\nThe evaluation of acute renal failure relies on fundamental scoring systems, biomarkers, and imaging modalities. Among the scoring systems, the most current and widely used is the KDIGO (Kidney Disease: Improving Global Outcomes) classification. According to the KDIGO definition, the diagnosis of AKI can be established when at least one of the following three criteria is met: an increase in serum creatinine of ≥0.3 mg\u002FdL within 48 hours, an increase in serum creatinine to ≥1.5 times baseline within 7 days, or a urine output of \\\u003C0.5 mL\u002Fkg\u002Fhour for more than 6 hours. AKI staging is performed based on these parameters.\n\nImaging modalities used in the assessment of renal function include renal ultrasonography (US), Doppler ultrasonography with measurement of the renal resistive index (RRI), renal MRI\u002FMR angiography, and renal computed tomography (particularly CT angiography). RRI is a non-invasive, bedside-applicable method that provides direct information about renal vascular resistance by evaluating renal arterial flow patterns.\n\nIn our clinic, the rationale of the present study is to measure preoperative HbA1c and Doppler-derived RRI values in patients undergoing isolated coronary artery bypass surgery, and to evaluate their relationship with postoperative KDIGO classification and Doppler RRI values in order to gain insight into the development of AKI.",[25,26,27,28],"Acute Kidney Injuries","Hemoglobin A1c Protein, Human","Coronary Bypass Graft Surgery","Renal Resistive Index",[30,31,32,33],"acute kidney injuries","hemoglobin A1c protein","coronary bypass graft surgery","renal resistive index","RECRUITING","2026-02-25",{"date":37,"type":38},"2026-03-03","ACTUAL",{"date":40,"type":38},"2026-01-20",{"date":42,"type":20},"2026-08-30",{"name":44,"class":45},"Osman Sila Aydin","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100586916","pocus-guided-diuresis-for-decompensated-heart-failure-100586916","NCT06921603","POCUS-Guided Diuresis for Decompensated Heart Failure","Point-of-Care Ultrasound-Guided Diuresis for Acute Decompensated Heart Failure to Reduce 30-Day Readmissions and Acute Kidney Injury","POCUSHF-GD","List the inclusion criteria:\n\n1. Age: Patients must be 18 years or older.\n2. Diagnosis: Must have a confirmed diagnosis of acute decompensated heart failure (ADHF).\n3. Treatment Plan: Patients must be planned for treatment with intravenous (IV) diuretics.\n4. POCUS Measurement: Must have an abnormal right internal jugular vein (RIJV) distensibility index (DI) of \\\u003C66% on point-of-care ultrasound (POCUS) at the time of admission.\n\nThese criteria ensure that participants are appropriately selected for the study and are likely to benefit from POCUS-guided diuretic management.\n\nList the exclusion criteria:\n\n1. Left Ventricular Assist Devices (LVAD): Patients with LVADs will be excluded due to their unique hemodynamics, which may interfere with study assessments.\n2. Anatomical Incompatibilities: Excludes patients with RIJV or superior vena cava thrombus, congenital heart disease, or severe tricuspid regurgitation, as these conditions may impair accurate POCUS measurements.\n3. Cardiomyopathy: Patients with hypertrophic or infiltrative cardiomyopathy will be excluded.\n4. End-of-Life Care: Patients receiving hospice care or comfort measures only will not be included in the study.\n5. Advanced Cancer: Patients with metastatic cancer will be excluded.\n6. Severe Liver Dysfunction: Patients with a MELD-Na score greater than 20, indicating severe liver dysfunction, will be excluded.\n7. End stage chronic kidney disease\n8. Inability to Provide Consent: Patients who are unable to provide informed consent, due to cognitive impairment or other reasons, will not be eligible.\n9. Inotropic Support: Patients requiring inotropic support at the time of enrollment will be excluded, as they represent a more severe heart failure profile that may not be suitable for this trial.",{"count":56,"type":20},588,"INTERVENTIONAL",[59],"NA","Heart failure occurs when the heart cannot pump blood effectively, leading to fluid buildup in the body. This can cause problems such as difficulty breathing, swelling, and extreme tiredness. In severe cases, these symptoms worsen to the point where hospitalization is required. Unfortunately, many patients with severe heart failure are readmitted to the hospital within 30 days after discharge, which is both physically and emotionally challenging for patients and places a significant financial burden on individuals and the healthcare system.\n\nAlthough symptoms such as difficulty breathing and swelling may improve during the hospital stay, some patients are discharged with excess fluid remaining in their bodies. This retained fluid often causes symptoms to worsen, leading to subsequent hospital readmissions. Inadequate management of fluid levels can also harm the kidneys, further complicating the patient's condition.\n\nThis study aims to improve care for heart failure patients by utilizing a simple, non-invasive tool to assess fluid levels more accurately at the bedside. The tool measures the size of a large blood vessel in the neck, providing key information about the pressure inside the heart. This information enables clinicians to determine the appropriate amount of medication needed to remove just the right amount of fluid. Properly managing fluid levels can help prevent kidney damage and improve overall patient outcomes.\n\nThe primary goal of this study is to evaluate whether this tool can reduce the number of patients readmitted to the hospital within 30 days of discharge. A secondary goal is to determine whether the tool can help protect kidney function by allowing for better fluid management. If successful, this approach has the potential to help heart failure patients stay healthier, reduce hospital visits, and lower healthcare costs.",[62,25],"Heart Decompensation, Acute",[64,65,66,67],"heart failure","point-of-care-ultrasound","readmission","acute kidney injury","2026-02-12",{"date":70,"type":38},"2026-02-17",{"date":72,"type":38},"2025-06-29",{"date":74,"type":20},"2026-12",{"name":76,"class":77},"University of Pittsburgh","OTHER",5,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100618756","c-reactive-protein--albumin-ratio-in-aki-100618756","NCT07335757","C-reactive Protein & Albumin Ratio IN AKI","Correlation Between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury in Patients With Acute Pancreatitis in Assiut University Hospitals.","Inclusion Criteria:\n\n* 1)patients who were diagnosed with Acute Pancreatitis by the following criteria: (i) abdominal pain mostly referred to the back, (ii) serum amylase and\u002For lipase greater than 3 times the upper limit of normal, and\u002For (iii) diagnostic findings from imaging (CT abdomen). 2)patients over 18 years old.\n\nExclusion Criteria:\n\n1\\) Pregnant or breastfeeding women 2)Length of hospital stay ≤ 24 h 3) Patients with CKD or end-stage renal disease. 4)patients with active malignancy. 5)patients with liver cirrhosis. 6)patients with active infections or surgeries\n\n\\-","60 Years",{"count":88,"type":20},150,"10 Days","Acute pancreatitis (AP), defined as acute inflammation of the pancreas, it's one of the most common diseases of the gastrointestinal tract leading to hospital admission.(1) The global incidence of AP is reported between 20 and 40 cases per 100,000 individuals, with an increasing trend over recent decades. (2) Its severity ranges from mild self-limited disease to severe acute necrotizing pancreatitis characterized by systemic complications and multi-organ failure. AKI is a frequent complication of severe acute pancreatitis, usually after the failure of other organs. (3) The aetiology of AP can be readily established in most patients. The most common causes include gallstones (40%-70%) and alcohol (25%-35%), medications as 6-mercaptopurine and azathioprine clearly can cause AP, infectious agents, and metabolic causes such as hypercalcemia and hypertriglyceridemia are rare causes (4) Acute kidney injury (AKI), affects approximately 15% of AP patients increasing to 69% in severe AP cases. AKI not only worsens the clinical status of AP patients but also significantly increases mortality risk and the likelihood of progressing to chronic kidney disease (CKD. Therefore, the challenge of early AKI identification and timely therapeutic intervention in AP patients remains critical. (2) Albumin (ALB), a negative acute-phase reactant synthesized by the liver, constitutes 40% to 60% of total plasma protein and decreases during inflammation. (5) Serum CRP refers to a positive acute phase reactant synthesized by the liver and its level in the blood elevates within hours as a response to inflammation and infection and it can be applied in follow-up owing to the short half-life, easy measurement, as well as the close association with prognosis of the disease. (6) We aimed to assess the Correlation between C-Reactive Protein to Albumin Ratio (CAR) and Acute Kidney Injury (AKI) in Patients with Acute Pancreatitis (AP) as a cost-effective, easily accessible, and reproducible prognostic biomarkers for inflammation obtained from standard blood tests.",[25],"NOT_YET_RECRUITING","2026-01-02",{"date":95,"type":38},"2026-01-13",{"date":97,"type":20},"2026-01-30",{"date":99,"type":20},"2029-01-30",{"name":101,"class":77},"Assiut University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":57,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100610239","phase-2-trimethoprim-sulfamethoxazole-tmpsmx-prophylaxis-after-acute-kidney-injury-to-prevent-post-discharge-infections-100610239","NCT07224997","Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections","Inclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.",{"count":109,"type":20},120,[111],"PHASE2","Official Title\n\nTrimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial\n\nBrief Summary\n\nAcute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP\u002FSMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP\u002FSMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety\u002Fadverse events, and healthcare utilization through 180 days.\n\nDetailed Description\n\nAdults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP\u002FSMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP\u002FSMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.\n\nStudy Design\n\n* Study Type: Interventional (Clinical Trial)\n* Primary Purpose: Prevention\n* Allocation: Randomized (1:1)\n* Intervention Model: Parallel Assignment\n* Masking: Double-blind (Participant, Outcomes Assessor)\n* Estimated Enrollment: 60 patients per group\n* Study Start Date: December 2025\n* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)\n* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)\n\nArms \\& Interventions\n\nExperimental: TMP\u002FSMX\n\n* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours\n* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours, for 90 days post-discharge.\n* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F\n\nPlacebo Comparator: Placebo\n\n* Intervention: Drug: Placebo (matching oral tablet)\n* Dosing: Matching schedule for 90 days post-discharge.\n\nConcomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.\n\nOutcome Measures\n\nPrimary Outcome\n\n• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and\u002For antimicrobial treatment initiation.\n\nSecondary Outcomes\n\n1. Time to first infection (days) within 90 days.\n2. Infection-related hospitalization within 90 and 180 days.\n3. All-cause mortality at 90 and 180 days.\n4. Emergency department visits or unplanned readmissions within 180 days.\n5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg\u002FdL, hyperkalemia ≥5.5 mmol\u002FL) through 180 days.\n6. C. difficile infection within 180 days.\n7. Recurrent AKI (KDIGO criteria) within 180 days.\n8. Medication adherence (pill counts and\u002For self-report) over 90 days.\n9. Major adverse kidney events over 90 days.\n\nEligibility Criteria\n\nInclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.\n\nContacts\u002FLocations\n\n* Lead Sponsor \u002F Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología\n* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609\n* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.\n\nEthics and Oversight\n\n* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.\n* IRB\u002FEthics approval: Comité de etica en investigacion, Protocol CEI 214\u002F25, Approval : October 16, 2025.\n* Written informed consent obtained from all participants prior to any study procedures.\n* Data",[25,114,115],"Acute Kidney Disease","Acute Kidney Injury (AKI)","2025-11-02",{"date":118,"type":38},"2025-11-05",{"date":120,"type":20},"2025-12-01",{"date":122,"type":20},"2027-07-01",{"name":124,"class":77},"Hospital Civil de Guadalajara",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":135,"conditions":136,"keywords":143,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100591796","this-is-an-observational-study-that-aims-to-demonstrate-postoperative-risk-factors-in-pediatric-cardiac-surgery-100591796","NCT06985082","This is an Observational Study That Aims to Demonstrate Postoperative Risk Factors in Pediatric Cardiac Surgery","Risk Factors for Postoperative Complications in Pediatric Cardiac Surgery: A Retrospective Observational Study","PEDS-CARE","Inclusion Criteria:\n\n* All patients under 18 years of age who underwent cardiac surgery\n\nExclusion Criteria:\n\n* Patients undergoing non-cardiac thoracic surgeries\n* Patients over 18 years of age\n* Pregnant women will be excluded from the study",{"count":134,"type":20},310,"This retrospective observational study aims to identify risk factors for postoperative complications in children undergoing cardiac surgery at a tertiary hospital in Brazil. By analyzing both electronic and physical medical records, researchers will examine demographic, clinical, surgical, and laboratory data, focusing on variables such as cardiopulmonary bypass (CPB) time, use of vasoactive drugs, and the occurrence of complications such as arrhythmias, acute kidney injury, and infections. Statistical analysis will include both descriptive and inferential methods, with multivariate logistic regression used to identify predictors of adverse outcomes. The study will be conducted between 2025 and 2027 with an estimated budget of R$1,000. Its goal is to inform preventive strategies and optimize perioperative care, ultimately improving patient outcomes and reducing hospital costs.",[137,25,138,139,140,141,142],"Arrhythmia","Sepsis","Pneumopathy","Thrombosis","Ventricular Asynchrony in Cardiac Surgery Patients","Pediatric Cardiac Surgery",[142,144,145],"Risk Factors Postoperative","Complications Posoperative","2025-05-14",{"date":148,"type":38},"2025-05-22",{"date":150,"type":20},"2025-05",{"date":152,"type":20},"2025-08",{"name":154,"class":77},"Instituto de Cardiologia do Rio Grande do Sul",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100573248","the-percent-of-aki-occurred-in-patient-with-comorbidities-undergoing-colonoscopy-100573248","NCT06743815","the Percent of AKI Occurred in Patient With Comorbidities Undergoing Colonoscopy","Predictors of AKI in Patient Undergoing Colonoscopy","Inclusion Criteria:\n\n* Adult patient aged \\>18 years old Patient with eGFR\\>30ml\u002Fmin\n\nExclusion Criteria:\n\n* patient with eGFR \\\u003C30ml\u002Fmin patient with serum electrolytes abnormalities patient with heart diseases (uncontrolled heart failure, unstable angina, myocardial infarction, coronary intervention within the previous 3 months) patients with ascites","90 Years",{"count":164,"type":20},113,"observation the percent AKI in patient with comorbidities undergoing colonoscopy",[25],"2024-12-17",{"date":169,"type":38},"2024-12-20",{"date":171,"type":20},"2025-01-30",{"date":173,"type":20},"2027-12",{"name":101,"class":77}]